English

Immunome, Inc.

EDGAR

IMNM Quarterly report (10-Q) · filed 2026-08-11

Annual consolidated revenue for 2025: about USD 6.941M, using the latest reported figures. The previous period, 2024, was about USD 9.041M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-61.7 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -120330000 USD Source
Operating Cash Flow: -58638000 USD Source

Free cash flow

-63.9 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -120330000 USD Source
Operating Cash Flow: -58638000 USD Source
Capital Expenditure: 5178000 USD Source
Capital Expenditure: 3002000 USD Source

Cash and cash equivalents: 218 million USD 2026-06-30 Source
Exact value

217700000 USD
Long-term debt including current maturities: 500 thousand Unit_Standard_USD_gQ8bJ0DqYE-48zWIBW1XSw 2021-03-31 Source
Exact value

500000 Unit_Standard_USD_gQ8bJ0DqYE-48zWIBW1XSw
Shares outstanding: 113 million shares 2026-06-30 Source
Exact value

113399202 shares

Reported share-count change

30.32% · 26.4 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

87012835 shares · 2025-06-30· Source
113399202 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 0 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 6941000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 6941000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 0 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 0 USD · 2026-04-01 – 2026-06-30 Source

Net income

-254 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -57457000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -212394000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -142494000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -53839000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -73127000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-209 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -142966000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -102456000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -190919000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -142966000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -58638000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -120330000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -58638000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

10.3 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 5686000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 4570000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 9685000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 5686000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 3002000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 5178000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 3002000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-219 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -142966000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -102456000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -190919000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -142966000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -58638000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -120330000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -58638000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 5686000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 4570000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 9685000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 5686000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 3002000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 5178000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 3002000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-11.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2025-12-31
Operating income: 2 of 11 periods available· newest 2025-12-31
Net income: 2 of 11 periods available· newest 2025-12-31
Operating cash flow: 2 of 11 periods available· newest 2025-12-31
Capital expenditure: 2 of 11 periods available· newest 2025-12-31
Total assets: 2 of 11 periods available· newest 2025-12-31
Total liabilities: 2 of 11 periods available· newest 2025-12-31
Current assets: 2 of 11 periods available· newest 2025-12-31
Current liabilities: 2 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 2 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 2 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-23.2%

Prior period

USD 9.04 million

2024-01-01 – 2024-12-31
Current period

USD 6.94 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

6941000 − 9041000 = -2100000 USD

9041000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
6941000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Immunome, Inc. · 2025-12-31 Immunome, Inc. (edgar:1472012) Year-over-year change in Revenue: -2100000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:05:27Z Snapshot: e115cbfa410130dee06f80b41b8b7979995b6cd8a48a01c79f9219c7a91e311a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1472012?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 6941000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm#1674640 Filing: 000119312526088172 Input fundies:Revenue: 9041000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm#1676292 Filing: 000119312526088172
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 80.57 million

Prior period

−USD 292.96 million

2024-01-01 – 2024-12-31
Current period

−USD 212.39 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-212394000 − -292963000 = 80569000 USD

-292963000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-212394000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Immunome, Inc. · 2025-12-31 Immunome, Inc. (edgar:1472012) Year-over-year change in Net income: 80569000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:05:27Z Snapshot: e115cbfa410130dee06f80b41b8b7979995b6cd8a48a01c79f9219c7a91e311a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1472012?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -212394000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm#1945751 Filing: 000119312526088172 Input fundies:NetIncome: -292963000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm#1876763 Filing: 000119312526088172
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 80.13 million

Prior period

−USD 110.79 million

2024-01-01 – 2024-12-31
Current period

−USD 190.92 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-190919000 − -110794000 = -80125000 USD

-110794000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-190919000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Immunome, Inc. · 2025-12-31 Immunome, Inc. (edgar:1472012) Year-over-year change in Operating cash flow: -80125000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:05:27Z Snapshot: e115cbfa410130dee06f80b41b8b7979995b6cd8a48a01c79f9219c7a91e311a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1472012?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -190919000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm#2021884 Filing: 000119312526088172 Input fundies:OperatingCashFlow: -110794000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm#2023740 Filing: 000119312526088172
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+35%

Prior period

USD 7.17 million

2024-01-01 – 2024-12-31
Current period

USD 9.69 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

9685000 − 7173000 = 2512000 USD

7173000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
9685000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Immunome, Inc. · 2025-12-31 Immunome, Inc. (edgar:1472012) Year-over-year change in Capital expenditure: 2512000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:05:27Z Snapshot: e115cbfa410130dee06f80b41b8b7979995b6cd8a48a01c79f9219c7a91e311a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1472012?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 9685000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm#2036456 Filing: 000119312526088172 Input fundies:CapitalExpenditure: 7173000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm#2038197 Filing: 000119312526088172
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 6.94 million 100% of revenue
Operating costs Derived USD 231.05 million 3,329% of revenue
Operating income −USD 224.11 million −3,229% of revenue
Tax, interest and other Derived −USD 11.72 million −169% of revenue
Net income −USD 212.39 million −3,060% of revenue

Cash

Operating cash flow −USD 190.92 million −2,751% of revenue
Capital expenditure USD 9.69 million 140% of revenue
Free cash flow Derived −USD 200.6 million −2,890% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2024 Operating loss: operating costs were 3,482% of revenue.
2025 Operating loss: operating costs were 3,329% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2024 2024-01-01 – 2024-12-31	9041000	314841000 Derived	-305800000	-12837000 Derived	-292963000	-117967000 Derived	Source 2024-01-01 – 2024-12-31: 9041000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -305800000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -292963000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -110794000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 7173000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	6941000	231054000 Derived	-224113000	-11719000 Derived	-212394000	-200604000 Derived	Source 2025-01-01 – 2025-12-31: 6941000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -224113000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -212394000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -190919000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 9685000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 6.9M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20242024-12-31	Revenue	9041000	Revenue: 9041000 Open source
20252025-12-31	Revenue	6941000	Revenue: 6941000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-23.2% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20242024-12-31	Year over year	No prior comparable period	Revenue: 9041000 Open source
20252025-12-31	Year over year	-23.2%	Revenue: 6941000 Open source Revenue: 9041000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -3,228.8% 2025

Net margin -3,060% 2025

Free cash flow margin -2,890.1% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20242024-12-31	Operating margin	-3,382.4%	Operating Income: -305800000 Open source Revenue: 9041000 Open source
20252025-12-31	Operating margin	-3,228.8%	Operating Income: -224113000 Open source Revenue: 6941000 Open source
20242024-12-31	Net margin	-3,240.4%	Net Income: -292963000 Open source Revenue: 9041000 Open source
20252025-12-31	Net margin	-3,060%	Net Income: -212394000 Open source Revenue: 6941000 Open source
20242024-12-31	Free cash flow margin	-1,304.8%	Revenue: 9041000 Open source Operating Cash Flow: -110794000 Open source Capital Expenditure: 7173000 Open source
20252025-12-31	Free cash flow margin	-2,890.1%	Revenue: 6941000 Open source Operating Cash Flow: -190919000 Open source Capital Expenditure: 9685000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -190.9M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20242024-12-31	Operating cash flow	-110794000	Operating Cash Flow: -110794000 Open source
20252025-12-31	Operating cash flow	-190919000	Operating Cash Flow: -190919000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -200.6M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20242024-12-31	Free cash flow	-117967000	Operating Cash Flow: -110794000 Open source Capital Expenditure: 7173000 Open source
20252025-12-31	Free cash flow	-200604000	Operating Cash Flow: -190919000 Open source Capital Expenditure: 9685000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

7.1% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20242024-12-31	Liabilities / assets	24.6%	Total Liabilities: 59076000 Open source Total Assets: 240241000 Open source
20252025-12-31	Liabilities / assets	7.1%	Total Liabilities: 48845000 Open source Total Assets: 683188000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

14.69× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20242024-12-31	Current assets / current liabilities	4.08×	Current Assets: 221339000 Open source Current Liabilities: 54307000 Open source
20252025-12-31	Current assets / current liabilities	14.69×	Current Assets: 660777000 Open source Current Liabilities: 44990000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2024 2024-01-01 – 2024-12-31	−USD 292.96 million Exact value Exact value: -292963000 USD 2024-01-01 – 2024-12-31: -292963000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Immunome, Inc. · 2024-12-31 Immunome, Inc. (edgar:1472012) Net Income: -292963000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:05:27Z Snapshot: e115cbfa410130dee06f80b41b8b7979995b6cd8a48a01c79f9219c7a91e311a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1472012/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -292963000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm#1876763 Filing: 000119312526088172 The citation records this snapshot. The page link may show a newer release later.	−USD 110.79 million Exact value Exact value: -110794000 USD 2024-01-01 – 2024-12-31: -110794000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Immunome, Inc. · 2024-12-31 Immunome, Inc. (edgar:1472012) Operating Cash Flow: -110794000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:05:27Z Snapshot: e115cbfa410130dee06f80b41b8b7979995b6cd8a48a01c79f9219c7a91e311a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1472012/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -110794000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm#2023740 Filing: 000119312526088172 The citation records this snapshot. The page link may show a newer release later.	USD 7.17 million Exact value Exact value: 7173000 USD 2024-01-01 – 2024-12-31: 7173000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Immunome, Inc. · 2024-12-31 Immunome, Inc. (edgar:1472012) Capital Expenditure: 7173000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:05:27Z Snapshot: e115cbfa410130dee06f80b41b8b7979995b6cd8a48a01c79f9219c7a91e311a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1472012/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7173000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm#2038197 Filing: 000119312526088172 The citation records this snapshot. The page link may show a newer release later.	−USD 117.97 million Calculation and evidence -110794000 − 7173000 USD Exact free cash flow: -117967000 USD 2024-01-01 – 2024-12-31: -110794000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 7173000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Immunome, Inc. · 2024-12-31 Immunome, Inc. (edgar:1472012) Free cash flow: -117967000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:05:27Z Snapshot: e115cbfa410130dee06f80b41b8b7979995b6cd8a48a01c79f9219c7a91e311a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1472012?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -110794000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm#2023740 Filing: 000119312526088172 Input fundies:CapitalExpenditure: 7173000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm#2038197 Filing: 000119312526088172 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 212.39 million Exact value Exact value: -212394000 USD 2025-01-01 – 2025-12-31: -212394000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Immunome, Inc. · 2025-12-31 Immunome, Inc. (edgar:1472012) Net Income: -212394000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:05:27Z Snapshot: e115cbfa410130dee06f80b41b8b7979995b6cd8a48a01c79f9219c7a91e311a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1472012/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -212394000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm#1945751 Filing: 000119312526088172 The citation records this snapshot. The page link may show a newer release later.	−USD 190.92 million Exact value Exact value: -190919000 USD 2025-01-01 – 2025-12-31: -190919000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Immunome, Inc. · 2025-12-31 Immunome, Inc. (edgar:1472012) Operating Cash Flow: -190919000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:05:27Z Snapshot: e115cbfa410130dee06f80b41b8b7979995b6cd8a48a01c79f9219c7a91e311a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1472012/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -190919000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm#2021884 Filing: 000119312526088172 The citation records this snapshot. The page link may show a newer release later.	USD 9.69 million Exact value Exact value: 9685000 USD 2025-01-01 – 2025-12-31: 9685000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Immunome, Inc. · 2025-12-31 Immunome, Inc. (edgar:1472012) Capital Expenditure: 9685000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:05:27Z Snapshot: e115cbfa410130dee06f80b41b8b7979995b6cd8a48a01c79f9219c7a91e311a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1472012/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9685000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm#2036456 Filing: 000119312526088172 The citation records this snapshot. The page link may show a newer release later.	−USD 200.6 million Calculation and evidence -190919000 − 9685000 USD Exact free cash flow: -200604000 USD 2025-01-01 – 2025-12-31: -190919000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 9685000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Immunome, Inc. · 2025-12-31 Immunome, Inc. (edgar:1472012) Free cash flow: -200604000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:05:27Z Snapshot: e115cbfa410130dee06f80b41b8b7979995b6cd8a48a01c79f9219c7a91e311a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1472012?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -190919000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm#2021884 Filing: 000119312526088172 Input fundies:CapitalExpenditure: 9685000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm#2036456 Filing: 000119312526088172 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

34 filings · 2,476 latest values · 2,476 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001472012, 1472012, IMNM, edgar:1472012

Also known as IMMUNOME, INC., IMMUNOME, INC., Immunome Inc., Immunome, Inc, Immunome, Inc., Immunome, Inc.

Immunome, Inc.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation